|
[1]
|
Gregory, A.D. and Houghton, A.M. (2011) Tumor-Associated Neutrophils: New Targets for Cancer Therapy. Cancer Research, 71, 2411-2416. [Google Scholar] [CrossRef]
|
|
[2]
|
Mantovani, A., Allavena, P., Sica, A. and Balkwill, F. (2008) Cancer-Related Inflammation. Nature, 454, 436-444. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Shaul, M.E. and Fridlender, Z.G. (2019) Tumour-Associated Neutrophils in Patients with Cancer. Nature Reviews Clinical Oncology, 16, 601-620. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Gooden, M.J., de Bock, G.H., Leffers, N., et al. (2011) The Prognostic Influence of Tumour-Infiltrating Lymphocytes in Cancer: A Systematic Review with Meta-Analysis. British Journal of Cancer, 105, 93-103. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Templeton, A.J., McNamara, M.G., Seruga, B., et al. (2014) Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. JNCI: Journal of the National Cancer Institute, 106, dju124. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2019) Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7-34. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Shao, Y., Wu, B., Jia, W., et al. (2020) Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. BMC Urology, 20, 90. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Greten, F.R. and Grivennikov, S.I. (2019) Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity, 51, 27-41. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
de Martino, M., Pantuck, A.J., Hofbauer, S., et al. (2013) Prognostic Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Localized Nonclear Cell Renal Cell Carcinoma. Journal of Urology, 190, 1999-2004. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Wei, Y., Jiang, Y.Z. and Qian, W.H. (2014) Prognostic Role of NLR in Urinary Cancers: A Meta-Analysis. PLOS ONE, 9, e92079. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Ohno, Y., Nakashima, J., Ohori, M., et al. (2012) Follow-Up of Neutrophil-to-Lymphocyte Ratio and Recurrence of Clear Cell Renal Cell Carcinoma. Journal of Urology, 187, 411-417. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Jagdev, S.P., Gregory, W., Vasudev, N.S., et al. (2010) Improving the Accuracy of Pre-Operative Survival Prediction in Renal Cell Carcinoma with C-Reactive Protein. British Journal of Cancer, 103, 1649-1656. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Pichler, M., Hutterer, G.C., Stoeckigt, C., Chromecki, T.F., Stojakovic, T., Golbeck, S., Eberhard, K., Gerger, A., Mannweiler, S., Pummer, K. and Zigeuner, R. (2013) Validation of the Pre-Treatment Neutrophil-Lymphocyte Ratio as a Prognostic Factor in a Large European Cohort of Renal Cell Carcinoma Patients. British Journal of Cancer, 108, 901-907. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
郭晓波. 肾癌患者外周血中性粒细胞淋巴细胞比值与其预后的关系分析[J]. 长治医学院学报, 2016, 30(2): 121-124.
|
|
[15]
|
Antoni, S., Ferlay, J., Soerjomataram, I., et al. (2017) Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. European Urology, 71, 96-108. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Burger, M., Catto, J.W., Dalbagni, G., et al. (2013) Epidemiology and Risk Factors of Urothelial Bladder Cancer. European Urology, 63, 234-241. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Babjuk, M., Böhle, A., Burger, M., et al. (2017) EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder: Update 2016. European Urology, 71, 447-461. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Xylinas, E., Kent, M., Kluth, L., et al. (2013) Accuracy of the EORTC Risk Tables and of the CUETO Scoring Model to Predict Outcomes in Non-Muscle-Invasive Urothelial Carci-noma of the Bladder. British Journal of Cancer, 109, 1460-1466. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Vartolomei, M.D., Porav-Hodade, D., Ferro, M., Mathieu, R., et al. (2018) Prognostic Role of Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC): A Systematic Review and Meta-Analysis. Urologic Oncology, 36, 389-399. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Tang, X., Du, P. and Yang, Y. (2017) The Clinical Use of Neu-trophil-to-Lymphocyte Ratio in Bladder Cancer Patients: A Systematic Review and Meta-Analysis. International Journal of Clinical Oncology, 22, 817-825. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Ogihara, K., Kikuchi, E., Yuge, K., et al. (2016) The Preoperative Neutrophil-to-Lymphocyte Ratio Is a Novel Biomarker for Predicting Worse Clinical Outcomes in Non-Muscle Invasive Bladder Cancer Patients with a Previous History of Smoking. Annals of Surgical Oncology, 23, 1039-1047. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Kimura, T. and Egawa, S. (2018) Epidemiology of Prostate Can-cer in Asian Countries. International Journal of Urology, 25, 524-531. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Kawahara, T., Yokomizo, Y., Ito, Y., et al. (2016) Pretreatment Neutro-phil-to-Lymphocyte Ratio Predicts the Prognosis in Patients with Metastatic Prostate Cancer. BMC Cancer, 16, 111. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Murata, H., Koyama, K., Takezawa, Y. and Nishigaki, Y. (2018) Baseline Neutrophil-to-Lymphocyte Ratio Predicts the Prognosis of Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate. Molecular and Clinical Oncology, 8, 587-591.
|
|
[25]
|
Kumano, Y., Hasegawa, Y., Kawahara, T., et al. (2019) Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide. BioMed Research International, 2019, Article ID: 9450838. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Mjaess, G., Chebel, R., Karam, A., et al. (2021) Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR) in Urological Tumors: An Umbrella Review of Evidence from Systematic Re-views and Meta-Analyses. Acta Oncologica, 60, 704-713. [Google Scholar] [CrossRef]
|
|
[27]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Can-cer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Nicholson, A.G., Tsao, M.S., Beasley, M.B., et al. (2022) The 2021 WHO Classification of Lung Tumors: Impact of Advances since 2015. Journal of Thoracic Oncology, 17, 362-387. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Zhu, X., Song, H., Chen, Y., et al. (2020) Neutro-phil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Blood to Distinguish Lung Cancer Patients from Healthy Subjects. Disease Markers, 2020, Article ID: 8844698. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Liu, J., Li, S., Zhang, S., et al. (2019) Systemic Immune-Inflammation Index, Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio Can Predict Clinical Outcomes in Patients with Metastatic Non-Small-Cell Lung Cancer Treated with Nivolumab. Journal of Clinical Laboratory Analysis, 33, e22964. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Raedler, L.A. (2015) Keytruda (Pembrolizumab): First PD-1 Inhibitor Ap-proved for Previously Treated Unresectable or Metastatic Melanoma. American Health & Drug Benefits, 8, 96-100.
|
|
[32]
|
Katayama, Y., Yamada, T., Chihara, Y., et al. (2020) Significance of Inflammatory Indexes in Atezoli-zumab Monotherapy Outcomes in Previously Treated Non-Small-Cell Lung Cancer Patients. Scientific Reports, 10, Arti-cle No. 17495. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Lababede, O. and Meziane, M.A. (2018) The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams. Oncologist, 23, 844-848. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Platini, H., Ferdinand, E., Kohar, K., et al. (2022) Neutro-phil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis. Medicina (Kaunas), 58, 1069. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Haggar, F.A. and Boushey, R.P. (2009) Colorectal Cancer Epide-miology: Incidence, Mortality, Survival, and Risk Factors. Clinics in Colon and Rectal Surgery, 22, 191-197. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Ait Ouakrim, D., Pizot, C., Boniol, M., et al. (2015) Trends in Colo-rectal Cancer Mortality in Europe: Retrospective Analysis of the WHO Mortality Database. BMJ, 351, h4970. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Moore, M.M., Chua, W., Charles, K.A. and Clarke, S.J. (2010) Inflamma-tion and Cancer: Causes and Consequences. Clinical Pharmacology & Therapeutics, 87, 504-508. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Haram, A., Boland, M.R., Kelly, M.E., et al. (2017) The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Colorectal Cancer: A Systematic Review. Journal of Surgical Oncology, 115, 470-479. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Kubo, T., Ono, S., Ueno, H., et al. (2014) Impact of the Perioperative Neutrophil-to-Lymphocyte Ratio on the Long-Term Survival Following an Elective Resection of Colorectal Carcinoma. International Journal of Colorectal Disease, 29, 1091-1099. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Grivennikov, S.I., Greten, F.R., Karin, M. et al. (2010) Immunity, Inflammation, and Cancer. Cell, 140, 883-899. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Ethier, J.L., Desautels, D., Templeton, A., et al. (2017) Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Breast Cancer: A Systematic Review and Meta-Analysis. Breast Cancer Re-search, 19, Article No. 2. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Mazaki, J., Katsumata, K., Kasahara, K., et al. (2020) Neutro-phil-to-Lymphocyte Ratio Is a Prognostic Factor for Colon Cancer: A Propensity Score Analysis. BMC Cancer, 20, Ar-ticle No. 922. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Arigami, T., Okumura, H., Matsumoto, M., et al. (2015) Analy-sis of the Fibrinogen and Neutrophil-Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma: A Promising Blood Marker of Tumor Progression and Prognosis. Medicine (Baltimore), 94, e1702. [Google Scholar] [CrossRef]
|
|
[44]
|
Bhat, T., Teli, S., Rijal, J., et al. (2013) Neutrophil to Lym-phocyte Ratio and Cardiovascular Diseases: A Review. Expert Review of Cardiovascular Therapy, 11, 55-59. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Huang, Z., Fu, Z., Huang, W. and Huang, K. (2020) Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Sepsis: A Meta-Analysis. The American Journal of Emergency Medicine, 38, 641-647. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Park, J.M. (2017) Neutrophil-to-Lymphocyte Ratio in Trauma Pa-tients. Journal of Trauma and Acute Care Surgery, 82, 225-226. [Google Scholar] [CrossRef]
|
|
[47]
|
Mazza, M.G., Lucchi, S., Tringali, A.G.M., et al. (2018) Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Mood Disorders: A Meta-Analysis. Progress in Neu-ro-Psychopharmacology & Biological Psychiatry, 84, 229-236. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Aggarwal, B.B., Vijayalekshmi, R.V. and Sung, B. (2009) Tar-geting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe. Clinical Cancer Research, 15, 425-430. [Google Scholar] [CrossRef]
|
|
[49]
|
Kao, S.C., Pavlakis, N., Harvie, R., Vardy, J.L., et al. (2010) High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Un-dergoing Systemic Therapy. Clinical Cancer Research, 16, 5805-5813. [Google Scholar] [CrossRef]
|